S. Sherman (Redwood City, US)

Stanford Medicine Orthopaedic Surgery
Seth Sherman is an Associate Professor of Sports Medicine at Stanford University. He completed orthopaedic surgical residency at the Hospital for Special Surgery in New York and Sports Medicine Fellowship at Rush University in Chicago; Illinois. Dr. Sherman is a third generation team physician and surgeon. He is a team physicians for the NCAA Division I Stanford Cardinal in the Pac 12 conference. His clinical interest is knee joint preservation; including ligament repair/reconstruction; osteotomy; meniscal repair/meniscal allograft transplantation (MAT); and cartilage restoration. He has a passion for the treatment of patellofemoral joint disorders. Dr. Sherman published over 50 peer reviewed text and has more than 100 podium presentations. He is on the Editorial Board of the Arthroscopy Journal and American Journal of Orthopedics. He is chair of the AAOS Sports Medicine/Arthroscopy Committee; deputy co-chair of the ICRS ‘NexGen’ committee; member of the Knee and Joint Preservation Committee for ISAKOS; Publication Committee for AOSSM; Advocacy Committee for AANA; and membership committee for the International ACL Study Group. Recent research interests include chondrocyte toxicity of injectable agents; in vivo modeling of the patellofemoral joint; MAT biomechanics; canine impact model evaluating bone marrow lesions.

Presenter Of 5 Presentations

Abstract Others

Moderator Introduction

Presentation Topic
Others
Date
12.04.2022
Lecture Time
12:00 - 12:03
Room
Bellevue
Session Type
Special Session
Extended Abstract (for invited Faculty only) Please select your topic

7.2.2 - Patient Specific Instrumentation for HTO and DFO: Presentation and Key Points of the Surgical Techniques

Presentation Topic
Please select your topic
Date
13.04.2022
Lecture Time
10:15 - 10:30
Room
Potsdam 3
Session Type
Industry Satellite Symposium
Extended Abstract (for invited Faculty only) Microfracture/Bone Marrow Stimulation

9.1.2 - Pivotal Study Results: Agili-C™ vs. Microfracture and Debridement for the Treatment of Joint Surface Lesions

Presentation Topic
Microfracture/Bone Marrow Stimulation
Date
13.04.2022
Lecture Time
12:15 - 12:30
Room
Potsdam 1
Session Type
Industry Satellite Symposium
Podium Presentation Biomaterials and Scaffolds

10.1.3 - Presence of Mild-Moderate Knee Osteoarthritis Does Not Affect the Clinical Outcome Using an Aragonite-Based Implant

Presentation Topic
Biomaterials and Scaffolds
Date
13.04.2022
Lecture Time
13:09 - 13:18
Room
Potsdam 1
Session Type
Free Papers
Disclosure
Peter Verdonk, CartiHeal, Consultant

Abstract

Purpose

OA has been considered a contra-indication for cartilage regenerative procedures. The objective of this study is to present the outcome following implantation of an aragonite-based implant (Agili-C™, CartiHeal Ltd, Israel) for the treatment of chondral/osteochondral defects in subjects with or without knee osteoarthritis (OA).

Methods and Materials

251 subjects suffering from knee chondral/osteochondral defects, with different grades of concurrent knee OA (Kellgren Lawrence score 0-3), were treated in a large multicenter, randomized, controlled trial: 167 subjects received the aragonite-based implant, and 84 subjects were treated by debridement/microfracture (control group). Clinical evaluation was performed using the KOOS score at 6, 12, 18 and 24 months. Subjects were stratified according to the grade of joint degeneration: none or minimal OA (K/L 0-1) vs. mild or moderate OA (K/L2-3). Results were then compared to assess whether the OA grade had an impact on the clinical outcome and to identify difference in performance between the implant and control group.

Results

In the implant group, 91 subjects had K/L 0-1, whereas 76 had K/L 2-3. At 6 months, the overall increase in KOOS score from baseline was 27.5 and 27.6 points respectively, well beyond the MCID. At the final 24 month follow-up, the increase was 43.9 points in K/L 0-1 and 41.9 points in K/L 2-3, without significant difference between these subgroups. Conversely, in the control group, the increase at 24 months was significantly lower: 23.2 points in K/L 0-1 subjects and 19 points in K/L 2-3 subjects. The scaffold group showed, therefore, superior outcome (p<0.0001), with a positive clinical trend throughout the entire study period.

Conclusion

The presence of mild-moderate OA did not impact the efficacy of the aragonite-based implant, which was able to provide significant clinical benefit even in patients with mild-moderate OA.

Collapse
Podium Presentation Allografts

16.3.8 - Risk for Failure After Index Osteochondral Allograft Transplantation: An Analysis of 1428 Cases

Presentation Topic
Allografts
Date
14.04.2022
Lecture Time
11:15 - 11:24
Room
Potsdam 1
Session Name
Session Type
Free Papers
Disclosure
No Significant Commercial Relationship

Abstract

Purpose

Osteochondral allograft transplantation has a demonstrated survivorship of upwards of 90% in the first five years following surgery. Although OCAs are highly effective, in some cases, subsequent surgeries may be required. There is currently limited data on the risk factors for reoperations following OCA and the interventions ultimately required. The purpose of this study was to utilize a large insurance database to evaluate the risk factors for failure within five years of OCA transplantation.

Methods and Materials

We queried the MarketScan database from 2007-2015 to identify patients who underwent primary OCA. Patients with previous ipsilateral anterior cruciate ligament reconstruction or meniscus surgery were excluded. Baseline demographic data and patient co-morbidities were documented. Failure of OCA, which we defined as ipsilateral revision OCA or conversion to unicomparmental or total knee arthroplasty, was documented through 5-years following index OCA. Multivariate regression analyses were conducted to identify risk factors for failure.

Results

A total of 1428 patients were included in the study. Mean age of the cohort was 31.6 years (SD 12.1) with 41.2% of the cohort being female. 9.7% of the cohort was obese at the time of initial OCA, 7.5% were active smokers, and 15.5% of the cohort had a previous cartilage restoring procedure. 0.3% underwent a revision or arthroplasty procedure within 5-years. Female sex (OR 1.61) and a history of microfracture prior to OCA (OR 1.21) increased risk for OCA failure. Concomitant osteotomy at the time of index OCA decreased odds of failure (OR 0.4, p – 0.0366).

Conclusion

Female sex and a history of microfracture increased odds for OCA failure, whereas a concomitant osteotomy at time of index surgery improved survivorship. This data should factor into a surgeon’s decision making when considering OCA for their patients with chondral defects of the knee.

Collapse

Moderator Of 4 Sessions

Bellevue Special Session
Session Type
Special Session
Date
12.04.2022
Time
12:00 - 13:00
Room
Bellevue
Session Description
The “next generation” of ICRS is focused on bridging gaps by identifying challenges and opportunities in relationships between generations of educators, clinicians and scientists, and surgeons with industry partners. We will also discuss important topics on diversity, equity, and inclusion in our field.
CME Evaluation
Potsdam 3 Industry Satellite Symposium
Session Type
Industry Satellite Symposium
Date
13.04.2022
Time
10:00 - 10:45
Room
Potsdam 3
Bellevue Morning Workshop
Session Type
Morning Workshop
Date
14.04.2022
Time
07:30 - 08:15
Room
Bellevue
Session Description
Experts will share their knowledge on successful grant writing.
Session Learning Objective
  1. In this instructional course, participants will learn how to write a successful grant application.
CME Evaluation

Meeting Participant Of

Bellevue Plenary Session
Session Type
Plenary Session
Date
14.04.2022
Time
17:30 - 18:30
Room
Bellevue
Session Description
All ICRS members, present in Berlin are expected to attend the ICRS General Member’s Assembly. Retired Members and Corporate Members have no right to vote but are most welcome to attend. It is of utmost importance that as many members as possible attend this important meeting and take part in decision-making and approval processes of our association.